Aequs moves to reshape its capital structure

Warrant conversion price: Rs 231.55 per share. Against the latest exchange snapshot as of 23 September 2026, the market capitalisation of Rs 16,360 Crores divided by 670,665,635 shares implies approximately Rs 243.94 per share. The warrant price is therefore:

• Rs 12.39 below the implied market price
• Approximately 5.08% discount
• 94.92% of the implied market price

The exact traded market quote is not available in the supplied price feed, so Rs 243.94 is an implied snapshot price rather than a quoted closing price. The Rs 231.55 warrant price is the SEBI pricing-formula floor price. ^[1]

Fully diluted equity base: Assuming all 28,071,690 warrants are converted and there are no other intervening equity changes:

• Existing shares: 670,665,635
• New shares from warrants: 28,071,690 ^[1]
• Projected post-conversion shares: 698,737,325
• Incremental dilution: approximately 4.19% versus the current share base

Conversion remains subject to shareholder and regulatory approvals, with exercise permitted within 18 months of allotment and conversion required by 31 December 2027. ^[1]

No rupee split has been disclosed for debt reduction, capacity expansion, or working capital.

• Capacity expansion: The stated primary use is expansion across Aequs’ aerospace and consumer businesses, including the Hosur facility, investments in subsidiaries and joint ventures, and general corporate purposes. ^[1]
• Debt reduction: No portion is specifically earmarked for repayment or reduction of existing debt. Instead, the equity is intended to provide the base against which Aequs raises term borrowings for the expansion. ^[1]
• Working capital: No separate working-capital allocation has been disclosed. “General corporate purposes” is mentioned, but it is not quantified or explicitly identified as working capital. ^[1]
• Funding timing, not use-of-proceeds split: Rs 325 crore, or 50% of the Rs 650 crore issue, is payable upfront on warrant allotment; the balance is payable on exercise. This is a payment schedule, not an allocation between end-uses. ^[1]

Bottom line: the disclosed Rs 650 crore is principally growth capital for aerospace and consumer capacity, with no specified amount for debt repayment or working capital. The proceeds are designed to support expansion-related borrowing rather than directly reduce debt. ^[1]

Yes—but with an important qualification: Aequs is signalling a preference for staggered conversion and dilution, not an avoidance of preferential issuance. The warrants are allotted preferentially upfront, but only half the cash is initially received and the equity, voting rights and remaining dilution are deferred until exercise.

Aequs

Aequs proposes up to 28.07 million promoter warrants at Rs 231.55 each, aggregating to approximately Rs 650 Crores. The promoter pays Rs 325 Crores at warrant subscription, with the balance payable when the warrants are converted; conversion can occur in one or more tranches up to 31 December 2027. Warrants carry no voting rights until conversion, and the initial Rs 325 Crores is forfeited if the warrants are not exercised by the deadline. ^[2]

Thus, approximately 50% of the proposed capital is upfront, with the remaining 50% conditional on exercise. Full conversion would raise the promoter-group holding from 59.09% to 60.73%, while the specific investor’s holding would rise from 14.99% to 18.40%. ^[2]

Sigma Advanced Systems

Sigma chose the more immediate route: a direct preferential allotment of 13.26 million equity shares at Rs 347 each, raising approximately Rs 460 Crores. The transaction increased paid-up equity capital to Rs 189.49 Crores, meaning the equity dilution occurred at allotment rather than being deferred through warrants. ^[3]

Capital-structure contrast: Sigma prioritised immediate funding and immediate equity issuance; Aequs is prioritising a staged funding commitment with delayed voting and dilution.

Astra Microwave

Astra is the closest structural precedent in the cited peer set. It issued 2.01 million convertible warrants at Rs 864 each, with a total potential issue size of Rs 173.99 Crores. Only 25% was payable upfront, with the remaining 75% due on conversion; Astra reported receipt of the 25% upfront amount by 31 March 2026. ^[4]

Aequs therefore uses the same broad warrant-based model, but with a larger upfront funding component—approximately 50% versus Astra’s 25%.

Zen Technologies

Zen used a QIP rather than promoter warrants. The issue had a base size of Rs 800 Crores, with the possibility of being increased to Rs 1,000 Crores, and was intended for working capital, acquisitions, strategic initiatives and general corporate purposes. ^[5]

Capital-structure contrast: Zen’s route was institutional equity fundraising, providing immediate equity capital but with broader investor participation; Aequs’s route is promoter-led and preserves the promoter’s ability to increase ownership over time.

Apollo Micro Systems

No transaction-specific warrant, QIP or preferential-allotment terms are reported in the cited evidence for Apollo. Its current ownership data shows promoter holding of 49.98% as of Q1 FY27, but that does not establish a comparable capital-raising strategy.

Paras Defence

No directly comparable capital-raising terms are reported in the cited evidence for Paras. Its promoter holding was 53.20% as of Q4 FY26, but ownership data alone is not evidence of whether the company prefers warrants, QIP or direct preferential equity.

Analyst read

The Aequs structure points to three deliberate forms of staging:

• Cash staging: only Rs 325 Crores is received initially; the balance depends on conversion.
• Dilution staging: existing shareholders face the full dilution only when warrants are converted.
• Control staging: the promoter receives no additional voting rights until conversion.

This is more dilution-conscious than Sigma’s immediate preferential equity allotment and broadly consistent with Astra’s warrant-led approach. However, it is not dilution-free: if fully converted, the share count and minority ownership percentages will be diluted. The company also does not have unconditional access to the full Rs 650 Crores until the promoter exercises the warrants.

A separate September 2026 disclosure reported that the promoter foundation pledged its 14.99% stake to secure a Rs 200 Crores finance facility. ^[6] That may be relevant context for the promoter’s financing capacity, but it does not by itself establish the rationale for choosing warrants.

Conclusion: the instrument choice does signal a preference for staggered equity dilution over immediate direct equity allotment, but the stronger interpretation is “preferential warrants with deferred conversion,” not “non-preferential funding.” Aequs receives an immediate capital commitment and upfront cash while retaining the option to defer the remaining dilution until the capital is required or the promoter elects to convert.